Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedMay 23, 2026
DataAggregated Company Financials
Companies56
  • 7D1.3%
  • 3M12.8%
  • 1Y45.3%
  • YTD-3.8%

The Pharma industry has gained 1.3% in the last week and Green Thumb Industries up 2.9%. This takes the industry's 12 month performance to a gain of 45%. As for the next few years, earnings are expected to grow by 32% per annum.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 23 May 2026CA$16.1bCA$12.1b-CA$1,903,345,344.718.2x-8.5x1.3x
Mon, 20 Apr 2026CA$14.9bCA$11.2b-CA$1,665,105,562.1414.5x-8.9x1.3x
Wed, 18 Mar 2026CA$14.0bCA$11.1b-CA$1,720,968,341.7111.9x-8.1x1.3x
Fri, 13 Feb 2026CA$14.2bCA$11.2b-CA$1,894,683,403.8214.8x-7.5x1.3x
Sun, 11 Jan 2026CA$16.6bCA$11.3b-CA$1,960,493,268.1216.8x-8.5x1.5x
Tue, 09 Dec 2025CA$14.1bCA$11.3b-CA$1,919,963,983.5214.4x-7.3x1.3x
Thu, 06 Nov 2025CA$15.3bCA$11.3b-CA$2,050,330,877.9426.6x-7.5x1.4x
Sat, 04 Oct 2025CA$17.9bCA$11.2b-CA$2,035,047,739.0438.3x-8.8x1.6x
Mon, 01 Sep 2025CA$18.1bCA$11.8b-CA$2,512,553,770.6739.9x-7.2x1.5x
Wed, 30 Jul 2025CA$12.0bCA$11.8b-CA$2,558,652,765.2816.3x-4.7x1x
Fri, 27 Jun 2025CA$9.7bCA$11.7b-CA$2,512,777,224.4916.7x-3.9x0.8x
Sun, 25 May 2025CA$23.4bCA$11.8b-CA$2,387,256,957.2817.5x-9.8x2x
Tue, 22 Apr 2025CA$9.7bCA$12.0b-CA$2,563,831,951.8617.9x-3.8x0.8x
Thu, 20 Mar 2025CA$10.6bCA$12.3b-CA$2,650,134,831.9120.1x-4x0.9x
Sat, 15 Feb 2025CA$12.5bCA$12.0b-CA$2,211,252,210.6523.8x-5.7x1x
Mon, 13 Jan 2025CA$12.4bCA$12.2b-CA$2,417,209,526.7728.7x-5.1x1x
Wed, 11 Dec 2024CA$13.6bCA$12.0b-CA$2,581,872,222.0023.1x-5.3x1.1x
Fri, 08 Nov 2024CA$15.0bCA$11.9b-CA$2,723,750,396.9517.8x-5.5x1.3x
Sun, 06 Oct 2024CA$18.5bCA$11.6b-CA$2,680,110,287.2427.4x-6.9x1.6x
Tue, 03 Sep 2024CA$17.1bCA$11.6b-CA$2,692,214,184.2420.2x-6.4x1.5x
Thu, 01 Aug 2024CA$20.1bCA$11.8b-CA$3,205,813,246.6719.4x-6.3x1.7x
Sat, 29 Jun 2024CA$21.1bCA$11.8b-CA$3,237,484,185.6218.5x-6.5x1.8x
Mon, 27 May 2024CA$21.8bCA$11.9b-CA$3,490,501,699.0812.8x-6.2x1.8x
Wed, 24 Apr 2024CA$22.9bCA$11.9b-CA$3,463,497,856.668.3x-6.6x1.9x
Fri, 22 Mar 2024CA$22.4bCA$11.9b-CA$3,492,881,259.179.5x-6.4x1.9x
Sun, 18 Feb 2024CA$22.3bCA$12.0b-CA$4,643,369,369.3410.4x-4.8x1.9x
Tue, 16 Jan 2024CA$21.7bCA$12.3b-CA$6,749,801,899.009.5x-3.2x1.8x
Thu, 14 Dec 2023CA$16.8bCA$12.4b-CA$6,761,536,562.008.3x-2.5x1.4x
Sat, 11 Nov 2023CA$16.7bCA$12.4b-CA$6,719,408,190.008.2x-2.5x1.3x
Mon, 09 Oct 2023CA$18.6bCA$12.4b-CA$7,334,632,248.0015x-2.5x1.5x
Wed, 06 Sep 2023CA$20.1bCA$13.0b-CA$7,921,923,060.0014.4x-2.5x1.5x
Fri, 04 Aug 2023CA$15.2bCA$13.3b-CA$9,744,920,850.0012.1x-1.6x1.1x
Sun, 02 Jul 2023CA$14.8bCA$13.2b-CA$9,514,993,610.0011.4x-1.6x1.1x
Tue, 30 May 2023CA$15.0bCA$13.4b-CA$10,466,111,147.0010.1x-1.4x1.1x
Price to Earnings Ratio

-1.4x


Total Market Cap: CA$15.0bTotal Earnings: -CA$10,466,111,147.00Total Revenue: CA$13.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.2% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market1.53%
Healthcare1.29%
Pharma1.30%
Pharma1.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GTII Green Thumb IndustriesCA$9.882.9%
+CA$61.3m		33.0%PE12.9x
CRON Cronos GroupCA$3.774.4%
+CA$60.2m		35.1%PS7x
TRUL Trulieve CannabisCA$10.363.1%
+CA$59.6m		79.9%PS1.2x
IAN iAnthus Capital HoldingsCA$0.01100.0%
+CA$34.9m		100.0%PS0.4x
VREO Vireo GrowthCA$0.553.8%
+CA$29.5m		12.2%PS1.7x

Latest News

RX
CA$13.70
BioSyent
7D
-5.1%
1Y
14.6%
NVRS
CA$1.75
Noveris Health Sciences
7D
-12.5%
1Y
250.0%
CURA
CA$4.62
Curaleaf Holdings
7D
-1.5%
1Y
288.2%
Narrative Update • May 21

CURA: Domestic Stabilization And International Expansion Will Support Future Re Rating

Analysts recently raised their Curaleaf Holdings price target by CA$1 to CA$5.50, citing expectations for steadier domestic operations alongside ongoing international growth opportunities. Analyst Commentary Recent research commentary around Curaleaf highlights a mix of optimism about international prospects and a more guarded stance on valuation and execution in the core business.
GUD
CA$8.35
Knight Therapeutics
7D
-0.9%
1Y
44.2%
Narrative Update • May 21

GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing

Analysts have raised their fair value estimate for Knight Therapeutics stock from CA$11.00 to CA$12.00, citing recent price target increases and renewed coverage that highlight modest adjustments to growth and margin assumptions, along with a slightly higher future P/E multiple. Analyst Commentary Bullish analysts have recently adjusted their outlook on Knight Therapeutics, pointing to factors that they see as supportive of the higher fair value estimate.
CL
CA$1.19
Cresco Labs
7D
6.3%
1Y
30.8%
QNTM
CA$12.79
Quantum BioPharma
7D
37.8%
1Y
-19.3%
CRON
CA$3.77
Cronos Group
7D
4.4%
1Y
35.1%
WEED
CA$1.46
Canopy Growth
7D
2.8%
1Y
-41.8%
VEXT
CA$0.26
Vext Science
7D
-11.9%
1Y
116.7%
CPH
CA$16.76
Cipher Pharmaceuticals
7D
-3.7%
1Y
34.9%
Analysis Article • May 14

Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings

Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
IAN
CA$0.01
iAnthus Capital Holdings
7D
100.0%
1Y
100.0%
VREO
CA$0.55
Vireo Growth
7D
3.8%
1Y
12.2%
GTII
CA$9.88
Green Thumb Industries
7D
2.9%
1Y
33.0%
TRUL
CA$10.36
Trulieve Cannabis
7D
3.1%
1Y
79.9%
INNO
CA$3.70
InnoCan Pharma
7D
-28.7%
1Y
-64.4%
NTLX
CA$0.15
Neurothera Labs
7D
-40.4%
1Y
n/a